Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Immune-related adverse events (irAEs) are very prevalent when treating patients with ipilimumab and nivolumab in combination, and 30–40% of patients discontinue the treatment for this reason. It is of high clinical relevance to investigate the consequences of discontinuing the treatment early since...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Morten Fink, Anders Schwartz Vittrup, Lars Bastholt, Inge Marie Svane, Marco Donia, Adam A. Luczak, Christina H. Ruhlmann, Louise Mahncke Guldbrandt, Ulrich Heide Koehler, Mette Lerche Winther, Eva Ellebaek, Charlotte Aaquist Haslund, Henrik Schmidt
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ipilimumab nivolumab melanoma immune-related adverse events DAMMED immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8adceece5386472fa24368dcbcd508ec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Ejemplares similares